| Literature DB >> 31238088 |
Thomas W Rösler1, Amir Tayaranian Marvian1, Matthias Brendel2, Niko-Petteri Nykänen3, Matthias Höllerhage1, Sigrid C Schwarz3, Franziska Hopfner4, Thomas Koeglsperger5, Gesine Respondek1, Kerstin Schweyer1, Johannes Levin5, Victor L Villemagne6, Henryk Barthel7, Osama Sabri7, Ulrich Müller8, Wassilios G Meissner9, Gabor G Kovacs10, Günter U Höglinger11.
Abstract
Tau is a microtubule-associated protein with versatile functions in the dynamic assembly of the neuronal cytoskeleton. Four-repeat (4R-) tauopathies are a group of neurodegenerative diseases defined by cytoplasmic inclusions predominantly composed of tau protein isoforms with four microtubule-binding domains. Progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease or glial globular tauopathy belong to the group of 4R-tauopathies. The present review provides an introduction in the current concept of 4R-tauopathies, including an overview of the neuropathological and clinical spectrum of these diseases. It describes the genetic and environmental etiological factors, as well as the contemporary knowledge about the pathophysiological mechanisms, including post-translational modifications, aggregation and fragmentation of tau, as well as the role of protein degradation mechanisms. Furthermore, current theories about disease propagation are discussed, involving different extracellular tau species and their cellular release and uptake mechanisms. Finally, molecular diagnostic tools for 4R-tauopathies, including tau-PET and fluid biomarkers, and investigational therapeutic strategies are presented. In summary, we report on 4R-tauopathies as overarching disease concept based on a shared pathophysiological concept, and highlight the challenges and opportunities on the way towards a causal therapy.Entities:
Keywords: 4R-tauopathy; Alzheimer’s disease; Argyrophilic grain disease; Corticobasal degeneration; Glial globular tauopathy; Microtubule-Associated protein tau; Progressive supranuclear palsy
Mesh:
Substances:
Year: 2019 PMID: 31238088 DOI: 10.1016/j.pneurobio.2019.101644
Source DB: PubMed Journal: Prog Neurobiol ISSN: 0301-0082 Impact factor: 11.685